Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms

The JAK1/2 inhibitor ruxolitinib has demonstrated significant benefits for patients with myeloproliferative neoplasms (MPN). However, patients often lose response to ruxolitinib or suffer disease progression despite therapy with ruxolitinib. These observations have prompted efforts to devise treatme...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2021-06, Vol.27 (12), p.3456-3468
Hauptverfasser:	Rampal, Raajit K, Pinzon-Ortiz, Maria, Somasundara, Amritha Varshini Hanasoge, Durham, Benjamin, Koche, Richard, Spitzer, Barbara, Mowla, Shoron, Krishnan, Aishwarya, Li, Bing, An, Wenbin, Derkach, Andriy, Devlin, Sean, Rong, Xianhui, Longmire, Tyler, Eisman, Shira Esther, Cordner, Keith, Whitfield, Justin T, Vanasse, Gary, Cao, Zhu A, Levine, Ross L
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Cyclin-Dependent Kinase 4 - metabolism Cyclin-Dependent Kinase 6 Humans Janus Kinase 1 Janus Kinase 2 - metabolism Mice Myeloproliferative Disorders - drug therapy Myeloproliferative Disorders - genetics Myeloproliferative Disorders - metabolism Neoplasms Nitriles - pharmacology Primary Myelofibrosis Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Signal Transduction
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!